Key Insights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed with results

Key Signals

100% success

1Total

P 2 (1)

Recruiting1

Completed1

100.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials

Health Outcomes by Neighborhood - Baltimore

High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis

Showing all 2 trials